FDA recommends excipients be used as physical chemical identifiers to thwart drug counterfeiters
This article was originally published in The Gold Sheet
Executive Summary
FDA has issued a draft guidance that recommends pharmaceutical manufacturers use "pharmacologically inactive" substances as physical-chemical identifiers (PCIDs) in solid oral dosage forms to fight drug counterfeiting. The draft guidance, entitled "Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting," notes that inks, pigments and flavors are some examples of substances that may be incorporated into solid dosage forms. The guidance notes that PCIDs should be "pharmacologically inactive so the ingredients can be treated as excipients." FDA recommends using "permissible direct food additives," including those affirmed as generally recognized as safe or those ingredients listed in the FDA Inactive Ingredient Guide to minimize toxicological risks. Various technologies that can be used to detect PCIDs include photolithography, holography, and laser scanning devices. The guide also addresses reporting or requesting approval to incorporate PCIDs into drug products as a postapproval change. Comments on the draft guidance are due Oct. 13
You may also be interested in...
FDA's Anticounterfeiting Guidance Dodges Secrecy Concerns
In final guidance on the use of physical-chemical identifiers in solid oral dosage form drugs, FDA avoids addressing commenters' qualms about confidentiality.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.